These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 30637361)

  • 41. Clinical characteristics of urosepsis caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumonia and their emergence in the community.
    Lee JC; Lee NY; Lee HC; Huang WH; Tsui KC; Chang CM; Lee CC; Chen PL; Wu CJ; Hsueh PR; Ko WC
    J Microbiol Immunol Infect; 2012 Apr; 45(2):127-33. PubMed ID: 22041167
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk factors for community acquired pediatric urinary tract infection with extended-spectrum-β-lactamase Escherichia coli - A case-control study.
    Collingwood JD; Wang L; Aban IB; Yarbrough AH; Boppana SB; Dangle PP
    J Pediatr Urol; 2023 Feb; 19(1):129.e1-129.e7. PubMed ID: 36344365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urinary tract infection caused by extended-spectrum β-lactamase-producing bacteria: Risk factors and antibiotic resistance.
    Albaramki JH; Abdelghani T; Dalaeen A; Khdair Ahmad F; Alassaf A; Odeh R; Akl K
    Pediatr Int; 2019 Nov; 61(11):1127-1132. PubMed ID: 31206219
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
    BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence of community-onset extended-spectrum β-lactamase-producing
    Richelsen R; Smit J; Anru PL; Schønheyder HC; Nielsen H
    Infect Dis (Lond); 2020 Aug; 52(8):547-556. PubMed ID: 32401562
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.
    Kotapati S; Kuti JL; Nightingale CH; Nicolau DP
    J Infect; 2005 Oct; 51(3):211-7. PubMed ID: 16230218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Ipekci T; Seyman D; Berk H; Celik O
    J Infect Chemother; 2014 Dec; 20(12):762-7. PubMed ID: 25179392
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Urinary tract infections owing to ESBL-producing bacteria: microorganisms change--clinical pattern does not.
    Özçakar ZB; Yalçınkaya F; Kavaz A; Kadıoğlu G; Elhan AH; Aysev D; Güriz H; Ekim M
    Acta Paediatr; 2011 Aug; 100(8):e61-4. PubMed ID: 21392102
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella spp. in a Singapore hospital: clinical spectrum.
    Chlebicki MP; Oh HM
    Ann Acad Med Singap; 2004 May; 33(3):302-6. PubMed ID: 15175768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
    Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
    N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.
    Jansåker F; Frimodt-Møller N; Sjögren I; Dahl Knudsen J
    J Antimicrob Chemother; 2014 Mar; 69(3):769-72. PubMed ID: 24107388
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Phenotypic and molecular identification of extended-spectrum beta-lactamase (ESBL) TEM and SHV produced by clinical isolates Escherichia coli and Klebsiella spp. in hospitals].
    González Mesa L; Ramos Morí A; Nadal Becerra L; Morffi Figueroa J; Hernández Robledo E; Alvarez AB; Marchena Bequer JJ; González Alemán M; Villain Plous C
    Rev Cubana Med Trop; 2007; 59(1):52-8. PubMed ID: 23427419
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of high mortality with extended-spectrum β-lactamase (ESBL) positive cultures in community acquired infections.
    Ray S; Anand D; Purwar S; Samanta A; Upadhye KV; Gupta P; Dhar D
    J Crit Care; 2018 Apr; 44():255-260. PubMed ID: 29220754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients.
    Colodner R; Rock W; Chazan B; Keller N; Guy N; Sakran W; Raz R
    Eur J Clin Microbiol Infect Dis; 2004 Mar; 23(3):163-7. PubMed ID: 14986159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk factors in community-acquired urinary tract infections caused by ESBL-producing bacteria in children.
    Topaloglu R; Er I; Dogan BG; Bilginer Y; Ozaltin F; Besbas N; Ozen S; Bakkaloglu A; Gur D
    Pediatr Nephrol; 2010 May; 25(5):919-25. PubMed ID: 20151161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antimicrobial resistance in community-acquired urinary tract infections in Paris in 2015.
    Chervet D; Lortholary O; Zahar JR; Dufougeray A; Pilmis B; Partouche H
    Med Mal Infect; 2018 May; 48(3):188-192. PubMed ID: 29054298
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P; Boroumand MA; Rahbar M; Douraghi M
    Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.